What Aindra does

Aindra Systems is an AI-powered MedTech company headquartered in Bengaluru, India, founded in 2012. The company builds a computational pathology platform called Astra that combines deep learning, computer vision, mechatronics, and optics to detect critical illnesses, with cervical cancer as its first beachhead. Its flagship product CervAstra analyzes pap smear samples at the point of care and returns Normal/Abnormal results within hours, replacing the multi-week turnaround typical in developing-world screening pathways. Supporting products include Aindra IS, a compact automated stainer for sample preparation, and Aindra VX (VisionX), a whole-slide telepathology imaging system; together the three form an integrated cervical cancer screening suite.

Aindra sells primarily through a direct enterprise field-sales motion to primary health centers, pathology laboratories, hospitals, and cancer institutes in India. Revenue is generated via hardware device sales (Aindra IS, Aindra VX) and point-of-care screening deployments (CervAstra), with no publicly disclosed pricing. The company is structured as a for-profit social enterprise that reinvests a portion of profits toward its mission of affordable healthcare access. It is supported by institutional funders including BIRAC (DBT Government of India), IUSSTF, Villgro, Millennium Alliance, IKP Knowledge Park, and Forge Forward, and maintains clinical validation partnerships with Kidwai Memorial Institute of Oncology, RV Metropolis, Rajarajeshwari Medical College, and KMC Manipal, alongside research partnerships with IIT Madras, IISc Bangalore, and IIT Mandi. CEO Adarsh Natarajan (MBA, IIM Bangalore) leads the company.

Name

Aindra

Legal name

Aindra Systems

Website

https://aindra.in

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Aindra Systems is an AI-powered MedTech company building a point-of-care cervical cancer screening platform (CervAstra) using computer vision and mechatronics, serving primary health centers, pathology labs, hospitals, and cancer institutes in India.

Ownership category

akta.pro rank

Product category

AI Medical Diagnostics - Computational Pathology

NAICS

Medical and Diagnostic Laboratories (62151), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• AI medical diagnostics
• Cervical cancer screening
• Computational pathology
• Telepathology systems
• Automated slide staining

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of AI-powered medical diagnostic devices including Aindra IS (automated stainer), Aindra VX (telepathology system), and Astra AI platform to healthcare facilities, pathology labs, and hospitals.
2. CervAstra Screening System: Point-of-care cervical cancer screening service at primary health centers enabling women to get screened and receive reports same day.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aindra builds and sells an AI-powered cervical cancer screening product suite for healthcare facilities. The Astra platform applies deep learning and computer vision to pap smear and whole-slide images; CervAstra delivers point-of-care Normal/Abnormal results within hours; Aindra IS is a compact automated slide stainer; and Aindra VX is a telepathology whole-slide imaging system that enables remote diagnosis.

Product overview

Aindra is an AI-powered MedTech company offering a unified product suite for cervical cancer screening. The core platform is Astra, an AI computational pathology system that powers CervAstra (point-of-care cervical cancer detection). Supporting products include Aindra IS (automated stainer for sample preparation) and Aindra VX/VisionX (telepathology whole slide imaging system). These products work cohesively as a 3-product suite to enable quick and accurate cervical cancer test results from sample preparation through AI-powered analysis.

Differentiator

Problem solved

Functional benefit

Brands

• Astra: AI platform built to detect critical illnesses such as Cancer; computational pathology platform that can be extended to build detection tools for multiple critical illnesses.
• CervAstra
• Aindra IS
• Aindra VX

Products and services

• Astra AI Platform AI platform for computational pathology that detects critical illnesses such as Cancer. Built from data assessed by experienced senior pathologists and designed to continuously learn from pathologist feedback through confirm/reject signals, serving as the core technology foundation powering Aindra's diagnostic products including CervAstra.
• CervAstra Point-of-care cervical cancer detection system that analyzes pap smear samples and delivers Normal or Abnormal results in under a few hours. Built using the Astra computational pathology platform and designed for deployment at primary health centers so women can walk in, get screened, and walk out with same-day reports.
• Aindra IS (Automated Stainer) Automated stainer for staining biological samples mounted on glass slides using state-of-the-art mechatronics and software. Sleek, compact, and portable device delivering crisp, clear, and high-quality staining without occupying large laboratory space.
• Aindra VX (VisionX Telepathology System) Telepathology system that captures extremely crisp images of whole slides for digital pathology. Enables fast turnaround times by allowing images captured at point-of-care to be transferred to clinicians for remote analysis, supporting telepathology and remote diagnosis.

Quantifiable outcome

• Results delivered in under a few hours instead of weeks
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• IIT Madras (IIT M)coreStrategic or Co-development PartnerResearch partner; one among the foremost institutes of national importance in higher technological education, basic and applied research. Faculty members including Dr. Shanti Bhattacharya serve as advisors for image acquisition device development.
• IISc BangalorecoreStrategic or Co-development PartnerResearch partner; university for research and higher education in science, engineering, design, and management.
• IIT MandicoreStrategic or Co-development PartnerResearch partner; Dr. Anil Kumar Sao serves as Chairperson of SCEE and provides technical advisory for patent pending technology in computer vision.
• RV MetropoliscoreStrategic or Co-development PartnerMedical partner with 34 years of experience; earned reputation as top pathology lab. Dr. Vani Ravikumar serves as advisor and has been instrumental in leading research and validation activities.
• Kidwai Memorial Institute of OncologycoreStrategic or Co-development PartnerMedical partner; Dr. Malathi M with 40+ years in Oncopathology is Principal Investigator for clinical validations and provides feedback for CervAstra.
• Rajarajeshwaria Medical College and HospitalminorStrategic or Co-development PartnerMedical partner for clinical validation and testing of diagnostic solutions.
• KMC ManipalminorStrategic or Co-development PartnerMedical partner for clinical validation.
• Union for International Cancer Control (UICC) / WHOcoreStrategic or Co-development PartnerMedical partner recognized by WHO; member of Union for International Cancer Control providing international validation and credibility.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• SigTuple: India-based AI medical imaging startup applying computer vision to blood, urine, and pathology analysis. Comparable as a domestic Indian AI-health peer with similar deep-tech approach to microscopy-based diagnostics, though serving different indications.
• Owkin: AI-biopharma platform with pathology AI and federated learning across hospital networks. Comparable to Aindra on the pathologist-supervised learning approach and on building proprietary data networks from clinical deployments.

Broad incumbents

• Hologic: Global leader in women's health diagnostics with the dominant ThinPrep cervical cancer cytology platform. Comparable because it directly competes in cervical cancer screening — Aindra's CervAstra is positioned as a point-of-care alternative to ThinPrep's lab-based workflow.
• Roche Diagnostics: Operates the cobas HPV/cervical cancer screening portfolio and a broader digital pathology effort. Comparable as an incumbent offering both cytology/HPV testing and emerging AI-pathology capabilities that Aindra competes with on the same cervical screening beachhead.
• Becton Dickinson (BD): Manufactures the SurePath cervical cancer screening system and a broad portfolio of diagnostic instruments including lab stainers. Comparable to Aindra's IS autostainer and CervAstra on the cytology sample-prep and screening workflow.
• Leica Biosystems (Aperio): Provides Aperio digital pathology scanners and lab staining instruments. Comparable to Aindra IS (autostainer) and Aindra VX (whole-slide imager) on the lab instrument layer of the pathology workflow.
• Philips (Digital Pathology): Offers IntelliSite Pathology Solution (whole-slide imaging) and AI-driven pathology tools. Comparable to Aindra VX (telepathology imager) on the slide-imaging/instrumentation layer and to Astra on the broader digital pathology workflow.

Direct peers

• Ibex Medical Analytics: AI-powered cancer diagnostics platform used in pathology labs worldwide for breast, prostate, and gastric cancer detection. Closely comparable to Aindra Astra on the AI-cancer-pathology workflow and pathologist-in-the-loop design.
• Paige.AI: AI pathology company with FDA-authorized prostate and breast cancer detection algorithms built on deep learning and pathologist feedback. Directly comparable to Aindra's Astra platform in applying continuous-learning AI to cancer pathology image interpretation.

Regional players

• Niramai: Bengaluru-based AI health startup focused on accessible, non-invasive breast cancer screening. Comparable as an Indian deep-tech cancer-screening peer with a similar 'AI for affordable healthcare' value proposition and point-of-care deployment model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aindrasystems
• Facebookfacebook.com/aindrasystems
• LinkedInlinkedin.com/company/3771299

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aindra